Docosahexaneoic Acid (22:6,n-3) Regulates Rat Hepatocyte SREBP-1 Nuclear Abundance by Erk- and 26S Proteasome-dependent Pathways
Overview
Affiliations
Insulin induces and dietary n-3 PUFAs suppress hepatic de novo lipogenesis by controlling sterol-regulatory element binding protein-1 nuclear abundance (nSREBP-1). Our goal was to define the mechanisms involved in this regulatory process. Insulin treatment of rat primary hepatocytes rapidly augments nSREBP-1 and mRNA(SREBP-1c) while suppressing mRNA(Insig-2) but not mRNA(Insig-1). These events are preceded by rapid but transient increases in Akt and Erk phosphorylation. Removal of insulin from hepatocytes leads to a rapid decline in nSREBP-1 [half-time (T1/2) approximately 10 h] that is abrogated by inhibitors of 26S proteasomal degradation. 22:6,n-3, the major n-3 PUFA accumulating in livers of fish oil-fed rats, suppresses hepatocyte levels of nSREBP-1, mRNA(SREBP-1c), and mRNA(Insig-2) but modestly and transiently induces mRNA(Insig-1). More importantly, 22:6,n-3 accelerates the disappearance of hepatocyte nSREBP-1 (T1/2 approximately 4 h) through a 26S proteasome-dependent process. 22:6,n-3 has minimal effects on microsomal SREBP-1 and sterol-regulatory element binding protein cleavage-activating protein or nuclear SREBP-2. 22:6,n-3 transiently inhibits insulin-induced Akt phosphorylation but induces Erk phosphorylation. Inhibitors of Erk phosphorylation, but not overexpressed constitutively active Akt, rapidly attenuate 22:6,n-3 suppression of nSREBP-1. Thus, 22:6,n-3 suppresses hepatocyte nSREBP-1 through 26S proteasome- and Erk-dependent pathways. These studies reveal a novel mechanism for n-3 PUFA regulation of hepatocyte nSREBP-1 and lipid metabolism.
Komiya Y, Sakazaki Y, Goto T, Kawabata F, Suzuki T, Sato Y iScience. 2024; 27(6):109816.
PMID: 38779480 PMC: 11108975. DOI: 10.1016/j.isci.2024.109816.
Regulation and targeting of SREBP-1 in hepatocellular carcinoma.
Su F, Koeberle A Cancer Metastasis Rev. 2023; 43(2):673-708.
PMID: 38036934 PMC: 11156753. DOI: 10.1007/s10555-023-10156-5.
Torrecilhas J, Pereira G, Vito E, Fiorentini G, Ramirez-Zamudio G, Fonseca L Metabolites. 2023; 13(10).
PMID: 37887367 PMC: 10608670. DOI: 10.3390/metabo13101042.
Schoeler M, Ellero-Simatos S, Birkner T, Mayneris-Perxachs J, Olsson L, Brolin H Nat Commun. 2023; 14(1):5329.
PMID: 37658064 PMC: 10474162. DOI: 10.1038/s41467-023-41074-3.
Key events in cancer: Dysregulation of SREBPs.
Li Y, Wu S, Zhao X, Hao S, Li F, Wang Y Front Pharmacol. 2023; 14:1130747.
PMID: 36969840 PMC: 10030587. DOI: 10.3389/fphar.2023.1130747.